Collaboration: Pfizer, Eyetech in deal for AMD, DME therapy

February 1, 2003

New York-Pfizer Inc. and Eyetech Pharmaceuticals Inc. will jointly develop and commercialize Eyetech's pegaptanib sodium (Macugen) as a potential treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME).